FHTX — Foghorn Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1822462 ·
Last close
$1.83
Market Cap
$109.73M
52W High
$7.61
52W Low
$1.73
ADV30
753,796
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 83,543,000 | — | 58,911,000 | 58,150,000 | 190,952,000 | 80,302,000 | 205,036,000 |
| Jun 2026 | 16,072,000 | — | -8,805,000 | -7,191,000 | 203,393,000 | 68,080,000 | 284,434,000 |
| Mar 2026 | 3,267,000 | — | -21,573,000 | -19,875,000 | 222,167,000 | 87,663,000 | 298,575,000 |
| Dec 2025 | 9,247,000 | — | -19,596,000 | -21,664,000 | 198,103,000 | 80,876,000 | 306,603,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-83,624,000
Investing CF
$16,735,000
Financing CF
$56,607,000
CapEx
$-57,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.16
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-601,383,000
Inventory
—
Receivables
—
ST Investments
$75,920,000
EBIT TTM
$8,937,000
Pretax Income TTM
$9,420,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$112,129,000
EBITDA
$10,422,000
Free Cash Flow
$-26,355,376
Enterprise Value
$11,768,686
Total Cash
$156,222,000
Total Debt
$43,868,000
Shares Out
59,962,650
Trailing EPS
$0.09
Book Value
$-0.23
ROE
—
ROA
2.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 30,909,000 | -82,107,000 | -74,283,000 | 198,103,000 | 306,603,000 | -108,500,000 | -86,099,000 |
| Dec 2024 | 22,602,000 | -100,285,000 | -86,620,000 | 283,982,000 | 329,510,000 | -45,528,000 | -100,406,000 |
| Dec 2023 | 34,155,000 | -107,906,000 | -98,426,000 | 285,916,000 | 363,106,000 | -77,190,000 | -118,106,000 |
| Dec 2022 | 19,228,000 | -117,137,000 | -108,882,000 | 404,883,000 | 404,771,000 | 112,000 | 193,612,000 |
TTM Snapshot
Revenues TTM
$36,739,000
NetIncome TTM
$-64,579,000
OpCashFlow TTM
—
Assets (Latest)
$203,393,000
Forward EPS
$-1.11
Max Pain — expiry 2026-12-18
max pain strike: $2.50 · spot: $1.79 · call oi: 428 · put oi: 746
Expected Move to 2026-12-18:
±$0.73
(40.50%) —
implied range
$1.06 –
$2.52
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | $111.18M | $0.40 | — |
| SCNX | Scienture Holdings, Inc. | $113.34M | $2.76 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $106.07M | $2.45 | — |
| ORGO | Organogenesis Holdings Inc. | $105.35M | $0.81 | — |
| UPB | Upstream Bio, Inc. | $115.10M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
Foghorn Therapeutics Inc. (FHTX) Q3 Earnings and Revenues Beat Estimates
2026-11-09 12:40 · Yahoo
Foghorn Therapeutics Provides Third Quarter 2026 Financial and Corporate Update
2026-11-09 12:22 · Yahoo
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
2026-11-03 12:00 · Yahoo
Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-28 13:00 · Yahoo
Foghorn Therapeutics (FHTX) Stock Fair Value Moves Lower After Pipeline And Lilly Reset
2026-10-22 01:24 · Yahoo
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
2026-10-02 18:12 · Yahoo
Sector Update: Healthcare Stocks Fall Late Afternoon
2026-10-01 19:57 · Yahoo
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
2026-10-01 19:51 · Yahoo
Top Midday Decliners
2026-10-01 18:44 · Yahoo
Lilly, Foghorn part ways; Wave’s FDA-approved plans
2026-10-01 16:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.